Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer

[1]  M. Gnant,et al.  BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy , 2014, Cancer Chemotherapy and Pharmacology.

[2]  M. Schreiber,et al.  The Pro Allele of the p53 Codon 72 Polymorphism Is Associated with Decreased Intratumoral Expression of BAX and p21, and Increased Breast Cancer Risk , 2012, PloS one.

[3]  D. Walerych,et al.  The rebel angel: mutant p53 as the driving oncogene in breast cancer , 2012, Carcinogenesis.

[4]  Wei Gu,et al.  Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence , 2012, Cell.

[5]  A. Goldhirsch,et al.  The triple-negative subtype: new ideas for the poorest prognosis breast cancer. , 2011, Journal of the National Cancer Institute. Monographs.

[6]  W. Wang,et al.  Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case–control study , 2011, Breast Cancer Research and Treatment.

[7]  Varda Rotter,et al.  Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. , 2011, Genes & cancer.

[8]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[9]  Magali Olivier,et al.  TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.

[10]  Y. Miyagi,et al.  Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy , 2009, BMC Cancer.

[11]  L. Cai,et al.  Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls , 2009, Journal of experimental & clinical cancer research : CR.

[12]  S. Wingren,et al.  Biological significance of allele specific loss of the p53 gene in breast carcinomas , 2009, Breast Cancer Research and Treatment.

[13]  A. Rosenberg,et al.  Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients , 2007, Cancer.

[14]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[15]  J. Jónasson,et al.  Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer , 2006, Breast Cancer Research.

[16]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[17]  J. Bergh,et al.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  M. Stratton,et al.  The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.

[19]  T. Crook,et al.  Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo , 2004, Oncogene.

[20]  M. Murphy,et al.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.

[21]  P. Lønning,et al.  The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  J. Godbold,et al.  Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. , 1997, Environmental health perspectives.

[23]  G. Hallmans,et al.  p53 polymorphisms and haplotypes in breast cancer. , 1996, Carcinogenesis.

[24]  R. Birgander,et al.  p53 polymorphisms and haplotypes in different ethnic groups. , 1995, Human heredity.

[25]  R. Birgander,et al.  Is p53 polymorphism maintained by natural selection? , 1994, Human heredity.

[26]  J. Simon,et al.  A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Lane,et al.  p53: oncogene or anti-oncogene? , 1990, Genes & development.